MedTrace Logo

TB Innovation Project: A Pre- and Post- Implementation Assessment (TIPPI)

NCT03948698 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 4159533

Last updated 2023-04-18

Study results available
· View outcomes & findings →

Summary

This evaluation will be conducted in ten countries involved in the Catalyzing Pediatric TB Innovation (CaP-TB) project: Cameroon, Cote D'Ivoire, Democratic Republic of Congo, Kenya, Lesotho, Malawi, Tanzania, Uganda, Zimbabwe and India. The CaP-TB project is a project designed to use innovative methods and capacity building to strengthen the health systems of developing countries in terms of pediatric TB case detection, early accurate diagnosis and effective treatment. This project is funded by Unitaid and is implemented by Elizabeth Glaser Pediatric AIDS Foundation.

EGPAF proposes to evaluate the implementation of CaP-TB in up to 450 sites in ten participating countries. This evaluation will assess the effects of CaP-TB innovative interventions on selected service delivery outcomes as compared to routine TB program in a sub-set of project sites in the ten countries.

Conditions

Interventions

OTHER

Innovative approached to pediatric TB care

Includes integration of TB care in non-TB entry points in facilities, decentralization from higher level clinics to lower levels, strengthening screening activities and building diagnosis and treatment capacity among healthcare workers

Sponsors & Collaborators

  • Elizabeth Glaser Pediatric AIDS Foundation

    lead OTHER

Principal Investigators

  • Jennifer Cohn, MD · Elizabeth Glaser Pediatric AIDS Foundation

  • Martina Casenghi, PhD · Elizabeth Glaser Pediatric AIDS Foundation

Eligibility

Max Age
14 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-01
Primary Completion
2021-09-30
Completion
2021-09-30

Countries

  • Cameroon
  • Côte d’Ivoire
  • Democratic Republic of the Congo
  • India
  • Kenya
  • Lesotho
  • Malawi
  • Tanzania
  • Uganda
  • Zimbabwe

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03948698 on ClinicalTrials.gov